JP2023526836A - コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤 - Google Patents

コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤 Download PDF

Info

Publication number
JP2023526836A
JP2023526836A JP2022570454A JP2022570454A JP2023526836A JP 2023526836 A JP2023526836 A JP 2023526836A JP 2022570454 A JP2022570454 A JP 2022570454A JP 2022570454 A JP2022570454 A JP 2022570454A JP 2023526836 A JP2023526836 A JP 2023526836A
Authority
JP
Japan
Prior art keywords
cov
sars
atr
cells
covid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526836A5 (https=
Inventor
シュテファン ルートヴィヒ
オリバー プランツ
ヘレン エリザ ホフマン
ユリア コッホ―ハイヤー
ミヒャエル シンドラー
Original Assignee
アトリバ セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトリバ セラピューティクス ゲーエムベーハー filed Critical アトリバ セラピューティクス ゲーエムベーハー
Publication of JP2023526836A publication Critical patent/JP2023526836A/ja
Publication of JP2023526836A5 publication Critical patent/JP2023526836A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022570454A 2020-05-20 2021-05-20 コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤 Pending JP2023526836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20175739.0 2020-05-20
EP20175739.0A EP3912623B1 (en) 2020-05-20 2020-05-20 Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
PCT/EP2021/063485 WO2021234097A1 (en) 2020-05-20 2021-05-20 Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm

Publications (2)

Publication Number Publication Date
JP2023526836A true JP2023526836A (ja) 2023-06-23
JP2023526836A5 JP2023526836A5 (https=) 2024-05-30

Family

ID=70802645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570454A Pending JP2023526836A (ja) 2020-05-20 2021-05-20 コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤

Country Status (11)

Country Link
US (1) US20230241014A1 (https=)
EP (2) EP3912623B1 (https=)
JP (1) JP2023526836A (https=)
KR (1) KR20230013077A (https=)
CN (1) CN116635022A (https=)
AU (1) AU2021277517A1 (https=)
BR (1) BR112022023013A2 (https=)
CA (1) CA3178137A1 (https=)
ES (1) ES2995196T3 (https=)
MX (1) MX2022014561A (https=)
WO (1) WO2021234097A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3973960B1 (en) 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
AU2021206684B2 (en) 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
US20240165099A1 (en) * 2022-09-30 2024-05-23 60 Degrees Pharmaceuticals Llc Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine
CN116270588B (zh) * 2022-12-26 2025-07-25 中国科学技术大学 Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069960A2 (en) * 2001-03-06 2002-09-12 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
JP2022529343A (ja) * 2019-04-16 2022-06-21 アトリバ セラピューティクス ゲーエムベーハー ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069960A2 (en) * 2001-03-06 2002-09-12 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
JP2022529343A (ja) * 2019-04-16 2022-06-21 アトリバ セラピューティクス ゲーエムベーハー ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAGONE, P. ET AL., AUTOIMMUN REV, vol. 19, no. 102571, JPN6025031002, 3 May 2020 (2020-05-03), pages 1 - 9, ISSN: 0005654145 *
LAISE, P. ET AL., BIORXIV, JPN6025031001, 17 May 2020 (2020-05-17), pages 1 - 20, ISSN: 0005654144 *

Also Published As

Publication number Publication date
US20230241014A1 (en) 2023-08-03
BR112022023013A2 (pt) 2022-12-20
AU2021277517A1 (en) 2022-12-08
ES2995196T3 (en) 2025-02-07
EP3912623A1 (en) 2021-11-24
CA3178137A1 (en) 2021-11-25
CN116635022A (zh) 2023-08-22
KR20230013077A (ko) 2023-01-26
EP4153159A1 (en) 2023-03-29
EP3912623B1 (en) 2024-07-31
EP3912623C0 (en) 2024-07-31
WO2021234097A1 (en) 2021-11-25
MX2022014561A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
JP2023526836A (ja) コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤
Zhang et al. Tick-borne encephalitis virus induces chemokine RANTES expression via activation of IRF-3 pathway
De-Simone et al. IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression
EP4146192A1 (en) Methods and compositions for the treatment of sars-cov-2
Han et al. Chemokine (CXC motif) ligand 4 is a restrictor of respiratory syncytial virus infection and an indicator of clinical severity
Wang et al. A77 1726, the active metabolite of the anti‐rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
Yuan et al. Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters
CN113311164A (zh) 新型冠状病毒（covid-19）及其他病毒感染的诊断和治疗
Bai et al. Cyclosporine A regulates influenza A virus-induced macrophages polarization and inflammatory responses by targeting cyclophilin A
US20230233483A1 (en) Compound and method for the treatment of coronaviruses
Wu et al. The role of innate immune system in respiratory viral infection related asthma
Du et al. Alisol B 23-acetate broadly inhibits coronavirus through blocking virus entry and suppresses proinflammatory T cells responses for the treatment of COVID-19
EP4186500A1 (en) Mek inhibitors for the prevention and treatment of long covid syndrome
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
US20230310421A1 (en) Molecules for use in the treatment of viral infections
Belouzard et al. Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
Bravo-Silva et al. Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections
Kerr et al. IFN-γ signaling is required for the efficient replication of murine hepatitis virus (MHV) strain JHM in the brains of infected mice
Yang et al. Transition of pseudorabies virus from latency to reactivation state selectively triggered by pathogenic bacteria
Berg et al. Respiratory syncytial virus load-dependent ciliated cell dedifferentiation and downregulation of immune response genes
Guayasamin et al. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector
KR102602043B1 (ko) 프랄라트렉세이트(Pralatrexate)를 유효성분으로 포함하는 항바이러스 조성물
WO2024141048A1 (en) Methods for treating coronavirus infections
US20180369302A1 (en) Epizootic hemorrhagic disease virus - tel aviv university (ehdv-tau) - oncolytic virus for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406